loading
Schlusskurs vom Vortag:
$20.77
Offen:
$20.88
24-Stunden-Volumen:
11,332
Relative Volume:
0.05
Marktkapitalisierung:
$614.73M
Einnahmen:
$4.12M
Nettoeinkommen (Verlust:
$-56.68M
KGV:
-
EPS:
-
Netto-Cashflow:
$-51.44M
1W Leistung:
-21.66%
1M Leistung:
-29.64%
6M Leistung:
-18.73%
1J Leistung:
+73.64%
1-Tages-Spanne:
Value
$19.84
$20.88
1-Wochen-Bereich:
Value
$19.84
$25.93
52-Wochen-Spanne:
Value
$6.58
$33.77

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name
Firmenname
Dianthus Therapeutics Inc
Name
Telefon
857-201-2700
Name
Adresse
300 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Mitarbeiter
53
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
DNTH's Discussions on Twitter

Vergleichen Sie DNTH mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
DNTH 20.13 614.73M 4.12M -56.68M -51.44M 0.00
VRTX 447.46 115.74B 10.63B -479.80M -1.35B 13.33
REGN 742.25 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 591.16 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.73 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.63 24.49B 3.30B -501.07M 1.03B 11.54

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-07-26 Eingeleitet Robert W. Baird Outperform
2024-06-27 Eingeleitet Cantor Fitzgerald Overweight
2024-05-16 Eingeleitet H.C. Wainwright Buy
2024-02-15 Eingeleitet Stifel Buy
2023-12-26 Eingeleitet Jefferies Buy
2023-11-22 Eingeleitet Wedbush Outperform
2023-10-30 Eingeleitet Guggenheim Buy
2023-09-28 Eingeleitet Raymond James Outperform
2022-08-25 Herabstufung Goldman Buy → Neutral
2022-01-06 Hochstufung Goldman Neutral → Buy
2021-08-20 Fortgesetzt Goldman Neutral
2021-08-03 Herabstufung JP Morgan Overweight → Neutral
2021-07-22 Bestätigt B. Riley Securities Buy
2021-06-29 Eingeleitet Cantor Fitzgerald Overweight
2021-06-15 Eingeleitet BTIG Research Buy
2021-05-18 Eingeleitet B. Riley Securities Buy
2021-01-07 Eingeleitet Mizuho Buy
2020-06-08 Hochstufung Goldman Neutral → Buy
2019-03-25 Herabstufung Goldman Buy → Neutral
2019-03-15 Eingeleitet Raymond James Outperform
Alle ansehen

Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten

pulisher
Nov 20, 2024

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest - MarketBeat

Nov 19, 2024
pulisher
Nov 16, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 8.1%Should You Sell? - MarketBeat

Nov 16, 2024
pulisher
Nov 14, 2024

What is HC Wainwright's Estimate for DNTH FY2024 Earnings? - MarketBeat

Nov 14, 2024
pulisher
Nov 12, 2024

Raymond James Forecasts Strong Price Appreciation for Dianthus Therapeutics (NASDAQ:DNTH) Stock - Defense World

Nov 12, 2024
pulisher
Nov 11, 2024

Evaluating Dianthus Therapeutics: Insights From 5 Financial Analysts - Benzinga

Nov 11, 2024
pulisher
Nov 11, 2024

Dianthus Therapeutics' (DNTH) Buy Rating Reiterated at HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 11, 2024

Oppenheimer Issues Positive Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat

Nov 11, 2024
pulisher
Nov 10, 2024

Dianthus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 10, 2024
pulisher
Nov 10, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade - Defense World

Nov 10, 2024
pulisher
Nov 08, 2024

A Glimpse Into The Expert Outlook On Dianthus Therapeutics Through 4 Analysts - Benzinga

Nov 08, 2024
pulisher
Nov 08, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $56.00 - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap UpHere's Why - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Dianthus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 08, 2024
pulisher
Nov 08, 2024

Dianthus Therapeutics Reports Q3 Progress and Financials - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

Dianthus Therapeutics Reports $342.6M Cash Runway, Advances Phase 3 CIDP Trial Plans | DNTH Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 07, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Analysts - Defense World

Nov 07, 2024
pulisher
Nov 07, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Rating of "Buy" by Analysts - MarketBeat

Nov 07, 2024
pulisher
Nov 04, 2024

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - The Manila Times

Nov 04, 2024
pulisher
Oct 23, 2024

Financial Analysis: Dianthus Therapeutics (NASDAQ:DNTH) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

SG Americas Securities LLC Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Oct 22, 2024
pulisher
Oct 15, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5%Should You Buy? - MarketBeat

Oct 15, 2024
pulisher
Oct 15, 2024

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - The Manila Times

Oct 15, 2024
pulisher
Oct 14, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 4.4%Here's What Happened - MarketBeat

Oct 14, 2024
pulisher
Oct 13, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $45.13 Consensus Target Price from Brokerages - MarketBeat

Oct 13, 2024
pulisher
Oct 09, 2024

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 4.5% – Still a Buy? - Defense World

Oct 08, 2024
pulisher
Oct 08, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 4.5%Should You Buy? - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Dianthus: Modest Opportunity With 2 Caveats (NASDAQ:DNTH) - Seeking Alpha

Oct 08, 2024
pulisher
Oct 07, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.7%Here's Why - MarketBeat

Oct 07, 2024
pulisher
Oct 04, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Sees Unusually-High Trading Volume – Still a Buy? - Defense World

Oct 04, 2024
pulisher
Oct 04, 2024

Marshall Wace LLP Sells 4,731 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Oct 04, 2024
pulisher
Oct 03, 2024

Dianthus started at outperform by Oppenheimer on DNTH103 opportunity - MSN

Oct 03, 2024
pulisher
Oct 03, 2024

Dianthus started at outperform by Oppenheimer on DNTH103 opportunity (NASDAQ:DNTH) - Seeking Alpha

Oct 03, 2024
pulisher
Oct 03, 2024

Oppenheimer Initiates Coverage on Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat

Oct 03, 2024
pulisher
Oct 03, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by Point72 Asset Management L.P. - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Down to $27.88 - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

Renaissance Technologies LLC Lowers Stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Oct 02, 2024
pulisher
Oct 02, 2024

American Century Companies Inc. Increases Stock Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Oct 02, 2024
pulisher
Sep 28, 2024

Fred Alger Management LLC Has $163,000 Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Sep 28, 2024
pulisher
Sep 26, 2024

Dianthus Therapeutics (NASDAQ:DNTH) Rating Reiterated by HC Wainwright - MarketBeat

Sep 26, 2024
pulisher
Sep 26, 2024

Expert Ratings For Dianthus Therapeutics - Benzinga

Sep 26, 2024
pulisher
Sep 25, 2024

Point72 Asia Singapore Pte. Ltd. Acquires 29,159 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Point72 Asia Singapore Pte. Ltd. Has $1.02 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

Sep 25, 2024
pulisher
Sep 24, 2024

Insider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells 40,831 Shares of Stock - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Dirk Kersten Sells 79,411 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Logos Global Management LP Sells 1,465,000 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Dyne Therapeutics (NASDAQ:DYN) Shares Down 3% - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Holdings Boosted by Great Point Partners LLC - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Dianthus Therapeutics (NASDAQ:DNTH) and Oramed Pharmaceuticals (NASDAQ:ORMP) Financial Review - Defense World

Sep 24, 2024

Finanzdaten der Dianthus Therapeutics Inc-Aktie (DNTH)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):